The Miriam Hospital recruiting for clinical trial of device to treat heart failure

October 30, 2015

PROVIDENCE, R.I. -The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack. The only site in Rhode Island to take part in the study, The Miriam has already completed the Parachute implant on two local patients. The Parachute device, an experimental treatment, is the first of its kind in the U.S.

"Presently, there are very few treatment options available for patients who experience enlargement of the left chamber of the heart, which makes this clinical trial crucial," said Paul Gordon, M.D., director of the cardiac catheterization laboratory at The Miriam Hospital and principal investigator of the trial at The Miriam Hospital. "Heart attack survivors currently suffering from heart failure may be candidates for the Parachute device research study and should discuss their condition with their physician."

Following a heart attack, many patients experience enlargement of the left ventricle causing heart failure symptoms such as shortness of breath. About 22 percent of men and 46 percent of women will develop heart failure within six years of having a heart attack. The Parachute device works by separating the damaged muscle from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its function. It is placed by an interventional specialist in the left chamber of the heart through a small catheter in the femoral artery. The minimally invasive procedure is performed in the catherization laboratory while a patient is awake but sedated and takes about 75 minutes.

The PARACHUTE IV randomized clinical trial explores the effectiveness of the device by comparing it to medical therapy and placement of an internal cardiac defibrillator (ICD) in approximately 500 patients with ischemic heart failure at up to 65 centers.

Heart disease is the leading cause of death for both men and women, according to the Centers for Disease Control and Prevention, killing about 610,000 people in the U.S. every year.
-end-
For more information on the study, or to find out if you qualify, please contact Catherine Gordon, BSN, at 401-793-4105.

About The Miriam Hospital

The Miriam Hospital is a 247-bed, not-for-profit teaching hospital affiliated with The Warren Alpert Medical School of Brown University with expertise in cardiology, oncology, orthopedics, men's health, and minimally invasive surgery. It is home to the state's first Joint Commission-certified Stroke Center and robotic surgery program. Its Total Joint Center has earned The Joint Commission's Gold Seal of Approval for its total knee and hip replacement programs. The hospital, which received more than $23 million in external research funding last year, is nationally known for its HIV/AIDS and behavioral and preventive medicine research, including weight control, physical activity and smoking cessation. Named 2015-16 best regional hospital in Rhode Island and the Providence metro area by U.S. News & World Report, The Miriam Hospital has been awarded Magnet Recognition for Excellence in Nursing Services five times and is a founding member of the Lifespan health system. Follow us on Facebook, Twitter (@MiriamHospital) and Pinterest.

Lifespan

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.